Company intelligence / Profile preview

Ascentawits Pharmaceuticals Ltd.

Shenzhen, Guangdong, Chinaascentawits.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company has multiple clinical-stage programs with their lead candidate AST-3424 (also known as OBI-3424) in Phase 1/2 for advanced malignant solid neoplasms. AST-3424 is a novel AKR1C3-activated prodrug that has shown efficacy in preclinical models. The company is conducting clinical trials for hepatocellular carcinoma and acute lymphoblastic leukemia in China.

Therapeutic areas: Oncology
Modalities: Small molecule-drug conjugates (SMDCs)Small molecule drugs
Industry: Biotech

Drug pipeline

3 assets

AST-003

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

OBI Pharma (for OBI-3424/AST-3424)

Beyond the preview

Go deeper on Ascentawits Pharmaceuticals Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascentawits Pharmaceuticals Ltd..

Explore the full profile